Rate Video

EHA 2020 | The relevance of MRD for CLL in the era of targeted therapies

Lydia Scarfò • 2 Jun 2020

Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, talks on the relevance of measurable residual disease (MRD) for chronic lymphocytic leukemia (CLL) in the era of targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

CAR-T and ibrutinib in combination: a promising treatment for CLL

Targeted therapies for CLL

Lydia Scarfò • 1 Jun 2020

Ibrutinib: characterizing CLL cells at relaspse

BTK and PLCG2 mutations in CLL patients taking ibrutinib

Lydia Scarfò • 2 Jun 2020

Related Videos

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021